A2650
Underlined text would be added to current law. Struck-through text would be removed.
Skip to main content
Go to top ] is old law to be omitted.
LBD01185-01-5
A. 2650 2
1 (b) Any prior-authorization requirements or other utilization review
2 measures for opioid analgesics, and any service denials made pursuant
3 thereto, shall not require use of opioid analgesic drug products without
4 abuse-deterrent properties in order to access abuse-deterrent opioid
5 analgesic drug products.
6 (c) Definitions. As used in this section:
7 (1) "Opioid analgesic drug product" means a drug in the opioid anal-
8 gesic drug class prescribed to treat moderate to severe pain or other
9 conditions, whether in immediate release or extended long acting release
10 form and whether or not combined with other drug substances to form a
11 single drug product or other dosage form.
12 (2) "Abuse deterrent opioid analgesic drug product" means a brand or
13 generic opioid analgesic drug product approved by the federal food and
14 drug administration with abuse-deterrence labeling claims indicating its
15 abuse-deterrent properties are expected to deter or reduce its abuse.
16 (3) "Cost-sharing" means any coverage limit, copayment, coinsurance,
17 deductible or other out-of-pocket patient expense requirements.
18 § 3. This act shall take effect on the one hundred twentieth day after
19 it shall have become a law, and shall apply to all policies and
20 contracts issued, renewed, modified, altered or amended on or after such
21 date.
Go to top
<link href="/styles/noscript_styles.css" rel="stylesheet"/>
Sitemap
Request Information
Directions and Maps
New York State Assembly
Speaker Carl E. Heastie
- Assembly Members
- Legislative Info
- Public Hearings
- Speaker's Press
- Assembly Reports
- Committees & More
- Bill Search Home
- Laws
- Legislative Calendar
- Public Hearing Schedule
- Assembly Calendars
- Assembly Committee Agenda
- Summary
- Actions
- Committee Votes
- Floor Votes
- Memo
- Text
- LFIN
- Chamber Video/Transcript
A02650 Summary:
| BILL NO | A02650 |
| SAME AS | SAME AS S00987 |
| SPONSOR | Sayegh |
| COSPNSR | |
| MLTSPNSR | |
| Amd ?273, Pub Health L; add ?3216-a, Ins L | |
| Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse. |
A02650 Text:
STATE OF NEW YORK ________________________________________________________________________ 2650 2025-2026 Regular Sessions IN ASSEMBLY January 21, 2025 ___________ Introduced by M. of A. SAYEGH -- read once and referred to the Committee on Insurance AN ACT to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Section 273 of the public health law is amended by adding a 2 new subdivision 11 to read as follows: 3 11. Any prior authorization requirements for opioid analgesic and any 4 service denials made pursuant thereto shall not require use of opioid 5 analgesic drug products without abuse-deterrent properties before 6 authorizing the use of abuse-deterrent opioid analgesic drug products. 7 § 2. The insurance law is amended by adding a new section 3216-a to 8 read as follows: 9 § 3216-a. Access to abuse-deterrent opioid medications. (a) An insur- 10 ance carrier or health plan shall provide coverage on its formulary, 11 drug list or other lists of similar construct for at least one abuse- 12 deterrent opioid analgesics drug product per opioid analgesics active 13 ingredient. 14 (1) Cost-sharing for brand name abuse-deterrent opioid analgesic drug 15 products covered pursuant to this section shall not exceed the lowest 16 cost-sharing level applied to brand name non-abuse deterrent opioid 17 drugs covered under the applicable health plan or policy. 18 (2) Cost-sharing for generic abuse-deterrent opioid analgesic drug 19 products covered pursuant to this section shall not exceed the lowest 20 cost-sharing level applied to generic non-abuse deterrent opioid drugs 21 covered under the applicable health plan or policy. 22 (3) An increase in patient cost-sharing or disincentives for prescri- 23 bers or dispensers shall not be allowed to achieve compliance with this 24 section. EXPLANATION--Matter in italics (underscored) is new; matter in brackets [Official text from the New York Legislature. Formatting has been adapted for reading on Ratifi.